Search results for: 'injection diseas in the developing world'

According to the National Institute of Health (NIH), there are more than 80 types of autoimmune diseases, of which less than 30 are diagnosable. Being 1 of the top 10 causes of death in the United States, there is a critical need in the market for the diagnosis and the treatment of both systemic diseases, such as lupus and rheumatoid arthritis, as ...

08 Jun 2022  |  North America  |  Market Research

Growth Opportunities in Sterile Injectable Outsourcing

Biologics Drive the Future Growth Potential of Sterile Injectable Outsourcing

Infographics

×

Injectables constitute one of the fastest growing segments in the pharmaceuticals space. Many drugs, including biologics, are going off patent in next 3 or 4 years, which will lead to an increase in the demand for generics and biosimilar injectables. The increase in onshoring and nearshoring of biopharmaceutical products for COVID-19 and next-gen...

Since the onset of the COVID-19 pandemic, molecular diagnostics mergers/acquisition transactions and product launches for infectious disease testing are indicating a pivot toward a new direction or an enhancement of portfolios. The emergence of saliva sample testing and the transition to PCR-based syndromic and direct-to-consumer testing for respir...

22 Aug 2022  |  North America  |  Frost Radar

Frost Radar™ for Economic Development: The United States, 2022

Texas, California and Georgia Emerge as Top States for Demonstrating Strong Investment Potential

Infographics

×

Key Issues Addressed

The Frost Radar™ for Economic Development for the United States determines the investment potential for each state measured by favorable state policies that will effectively drive inward investment and that are driven by social factors. This report explores key strengths and weaknesses of the the US economy through state-level assessments of growt...

This research service covers the U.S. injectable drug pipeline in 2009. Included are technology trends, Phase III pipeline analysis, selected Phase II and I pipeline analysis. The market is segmented by injectable drug delivery route: subcutaneous injectables, intravenous injectables, intramuscular injectables, and others. Major market challenges,...

06 Oct 2021  |  North America  |  Market Research

US Chronic Disease Management Growth Opportunities

Future Growth Potential Enhanced by the Pandemic and Growth Opportunities in Chronic Disease Management

Infographics

×

Key Issues Addressed

The prevalence of chronic diseases has continued to rise, and the expenses of managing them or treating the complications arising from poor management cost the US healthcare system hundreds of billions of dollars each year. Clearly, physicians alone cannot control this rising challenge, and to ensure behavioral change, several tools and approaches ...

Management of infectious diseases remains a critical challenge for public health professionals who face increasing demand to control the spread of existing and novel diseases. To provide appropriate healthcare assistance, it is imperative to diagnose the exact form of infection from an array of complicated symptoms expressed by the host. As the out...

As clinical pipelines globally witness a surge in novel complex therapies, the clinical trial industry demands new tools in predictive analytics to improve trial design, planning, and execution. Artificial intelligence is gaining large-scale recognition as support for decentralized trial designs, thus enabling patient-centric clinical trial designs...

The global pharmaceutical research and development (R&D) pipeline accounts for more than 21,000 molecules, as of April 2023, indicating a 5.8% hike over 2022, with more than 6,100 molecules in active development. In general, however, the pharma/biopharma industry has stagnated with respect to R&D activity. Overall R&D expenditure totals about $276....